<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850278</url>
  </required_header>
  <id_info>
    <org_study_id>2007-006265-32</org_study_id>
    <nct_id>NCT00850278</nct_id>
  </id_info>
  <brief_title>Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors</brief_title>
  <acronym>FLT</acronym>
  <official_title>Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of the radiopharmaceutical
      3'-deoxy-3'-[F-18]fluorothymidine, [F-18]FLT, a tracor of cell proliferation, using Positron
      Emission Tomography (PET) imaging for the tumor diagnosis and prognosis in a group of 50
      patients with different type of brain tumors.[F-18]FLT PET imaging will be compared to the
      current used imaging techniques of MRI, spectroscopy imaging, PET imaging using [11C]MET
      tracer, immunohistochemical analysis and clinical parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluated the aggressive potential of brain tumors related to cell proliferation index measured by [18F]FLT</measure>
    <time_frame>Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficiency of [18F]FLT with [11C]MET</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To define relations between [18F]FLT uptake and clinical, histological and radiological parameters</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To define relations between [18F]FLT uptake and patient survival</measure>
    <time_frame>J90</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cancer</condition>
  <condition>Brain Tumors</condition>
  <arm_group>
    <arm_group_label>FLT-PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FLT-PET imaging</intervention_name>
    <description>Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.</description>
    <arm_group_label>FLT-PET imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults aged between 18 and 70 years

          -  must have operable grade II, III or IV glioma, recurrent high grade glioma or brain
             metastases

          -  KPS &gt;= 70%

          -  must have the understanding and ability to sign an informed consent document

          -  must have adequate liver and kidney function

          -  be male or non-pregnant, non-lactating females

          -  patients who are fertile must agree to use an effective method of contraception during
             participation in the study

          -  the following laboratory results : absolute neutrophil count &gt;= 1500 cells/µl,
             platelet count &gt;= 100000 cells/µl, SGOT &lt;= 2.5 x ULN, serum creatinine &lt;= 1.5 x ULN.

        Exclusion Criteria:

          -  contraindication to surgery

          -  concomitant radio-, chemo-, or immunotherapy

          -  history of significant dementia

          -  known diagnosis of Human Immunodeficiency Virus (HIV) infection

          -  patient with hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Sébastien Guillamo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Michel Derlon, Pr</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain tumor</keyword>
  <keyword>[18F]FLT</keyword>
  <keyword>[11C]MET</keyword>
  <keyword>TEP-imaging</keyword>
  <keyword>tumor cell proliferation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

